Essential Estrogens™ - 24 hr

Estrone is the predominant oestrogen in postmenopausal women, synthesised by peripheral aromatisation of androstenedione in adipose tissue and other sites. During reproductive years it is less potent than oestradiol but serves as a reservoir via interconversion by 17β-hydroxysteroid dehydrogenase. Urinary oestrone represents a cumulative integrated measure of secretion and peripheral metabolism over the collection period.

Elevated oestrone in postmenopausal women may reflect increased adipose aromatase activity or exogenous hormone exposure, a pattern associated with endometrial and breast cancer risk. Low oestrone in premenopausal women can signal ovarian insufficiency or hypothalamic amenorrhoea. The 24-hour integrated measurement reduces fluctuation seen with single serum samples.

Estradiol is the most potent endogenous oestrogen, secreted primarily by ovarian granulosa cells in premenopausal women and by peripheral conversion of oestrone and testosterone after menopause. Urinary oestradiol captures cumulative production and first-pass hepatic metabolism, providing a time-averaged picture distinct from the moment-in-time snapshot of serum oestradiol.

Oestradiol is central to reproductive function, bone health, cardiovascular protection, and cognitive well-being. A 24-hour urine collection smooths diurnal and pulsatile variation, making it useful for assessing overall oestrogenic status in perimenopause, monitoring oestrogen replacement, and evaluating suspected hypoestrogenism in women with amenorrhoea or premature ovarian insufficiency.

Estriol is a weak oestrogen produced in small amounts by ovarian and adrenal pathways, with large placental synthesis during pregnancy. Outside pregnancy, oestriol represents a terminal metabolite of oestrone and oestradiol, and its measurement in 24-hour urine reflects the overall flux through oestrogenic pathways. It has the lowest receptor affinity of the three classical oestrogens.

Non-pregnant oestriol is primarily of interest in functional and integrative medicine, where it is thought to reflect metabolic clearance of more potent oestrogens. Some practitioners use oestriol in topical or oral bioidentical formulations, citing a favourable safety profile for vaginal and urogenital symptoms, though its routine measurement in non-pregnant women lacks strong evidence-based clinical indications.

2-Hydroxyestrone is a principal catechol oestrogen metabolite formed by cytochrome P450 1A1/1A2 hydroxylation of oestrone and oestradiol. It is considered a 'favourable' or 'protective' metabolite with weak oestrogenic activity, minimal proliferative effect, and possible antiproliferative actions. It is rapidly methylated by catechol-O-methyltransferase to methoxy derivatives or conjugated for excretion.

Higher 2-hydroxylation relative to other pathways has been associated in some observational studies with lower breast and endometrial cancer risk, though causality is unproven. Practitioners use the absolute level and ratio of 2-hydroxyestrone to the 16α and 4-hydroxy pathways as a metabolic 'profile', informing nutritional and supplement interventions aimed at favouring the 2-pathway.

16α-Hydroxyestrone is formed by CYP3A4-mediated 16α-hydroxylation of oestrone. Unlike the catechol metabolites, it retains full oestrogenic potency, binds the oestrogen receptor avidly, and is not readily inactivated, giving it prolonged biological activity. It can form covalent DNA adducts and has been termed a 'high-risk' or 'proliferative' metabolite in the functional-medicine literature.

Epidemiological data link higher 16α-OHE1 (or a lower 2-OHE1 : 16α-OHE1 ratio) with increased breast cancer risk in some but not all studies; the association remains contested. Practitioners interpret elevated 16α-OHE1 or an unfavourable ratio as a marker of increased proliferative drive and may recommend dietary changes, indole-3-carbinol, or weight loss to shift metabolism toward the 2-pathway.

4-Hydroxyestrone is a minor catechol oestrogen metabolite formed by CYP1B1-mediated hydroxylation. It undergoes redox cycling to quinones that can form depurinating DNA adducts, initiating mutations. Because of this genotoxic potential, 4-OHE1 is considered the 'highest-risk' oestrogen metabolite, though it normally represents a small fraction of total metabolism.

Elevated 4-hydroxyestrone has been associated with increased breast cancer risk in mechanistic and some case-control studies. CYP1B1 polymorphisms, environmental exposures, and impaired conjugation may raise 4-OHE1 levels. Practitioners use this marker to identify patients who may benefit from increased antioxidant support, cruciferous vegetable intake, and optimisation of methylation and conjugation pathways.

This ratio compares the flux through the 'protective' 2-hydroxylation pathway with the genotoxic 4-pathway. A higher ratio indicates preferential metabolism toward 2-OHE1, reducing formation of DNA-damaging 4-hydroxy quinones. The ratio is influenced by CYP1A1, CYP1B1 polymorphisms, cruciferous vegetable intake, and body composition.

The 2:4 ratio is used in functional and integrative oncology as a modifiable biomarker of oestrogen metabolism safety. Interventions to raise the ratio include indole-3-carbinol or diindolylmethane supplementation, weight loss, and cruciferous vegetable consumption, though randomised data linking ratio changes to cancer outcomes are lacking.

This ratio compares the protective, rapidly inactivated 2-pathway with the potent, slowly cleared 16α-pathway. A higher ratio reflects preferential 2-hydroxylation and has been hypothesised to reduce oestrogenic proliferative drive on breast and endometrial tissue. Diet, body fat, exercise, and genetic polymorphisms all influence the ratio.

The 2:16α ratio gained prominence in the 1990s as a potential breast cancer risk marker; subsequent studies have shown mixed results. Despite the lack of definitive evidence, functional and integrative practitioners continue to use it to guide nutritional and lifestyle interventions aimed at modulating oestrogen metabolism, particularly in patients with strong family history or dense breast tissue.